Member Info for JohnHenry

The sellers allowed this sportrader

Closing long positions.

Chatting with my IG account manager, apparently there has been a couple of clients with large holding closing their open positions this week.

Only valued at 1/2 billion due to the huge revenue and profit forecast.

You dont get something for nothing.

Its not undervalued compared to others namely NCYT as GDR is not making any revenue yet.

NCYT rerating due the the massive UK contract just announced.

Piling out

out of that 575K, 300K was mine, SB taken with IG

Its not the UT

No No the uncrossing trade after 17.00 at Mid is the spread betters through out the day.

Thats the spread betters uncrossing trade from today, so not a 575k buy.

is having a rest day.

Absolutely, the revenue generating Daddy of the Covid Testing stocks NCYT continues to power ahead.
GDR needs to start delivering Revenue.

At present there is next to no value price into the ORPH for Imutex.
Its obvious to a Blind Man that the PA is being driven higher by the revenue generating deals. As suggested earlier by PeterS23 that Imutex could be worth 5p of ORPH present price 20p minus 15p is absolute dawdle.

pushing the offer down , imho they have another line of stock to clear.

DC69 You do realise that GDR are just one of many companies developing a Saliva Assay ?

Astra Zeneca will use Human Challenge Studies Pfizer will not, pretty clear to most I would imagine.

Ihavenoclue question what revenue backs up a £25M MKT Cap on there other products.

my guess is that BEGO have a slight overhang to clear, probably another placing seller.

Also a shed load of sellers to clear.

Looking likely to break out of a wedge pattern the next few days.